Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial

This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of 2 doses of the HPV-16/18 AS04-adjuvanted vaccine (HPV-16/18(2D)) vs. 2 or 3 doses of the HPV-6/11/16/18 vaccine (HPV-6/11/16/18(2D) and HPV-6/11/16/18(3D)) in healthy girls aged 9–14 y. Girls were ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Ting Fan, Liu, Anthony Pak-Yin, Lim, Fong Seng, Thollot, Franck, Oh, Helen May Lin, Lee, Bee Wah, Rombo, Lars, Tan, Ngiap Chuan, Rouzier, Roman, Friel, Damien, De Muynck, Benoit, De Simoni, Stéphanie, Suryakiran, Pemmaraju, Hezareh, Marjan, Folschweiller, Nicolas, Thomas, Florence, Struyf, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514190/
https://www.ncbi.nlm.nih.gov/pubmed/26062002
http://dx.doi.org/10.1080/21645515.2015.1050570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514190/
https://www.ncbi.nlm.nih.gov/pubmed/26062002
http://dx.doi.org/10.1080/21645515.2015.1050570

Ejemplares similares